Header
Ihr Suchergebnis
Sie recherchieren derzeit unangemeldet.Melden Sie sich an (Login) um den vollen Funktionsumfang der Datenbank nutzen zu können.
Sie suchen in allen Bereichen nach dem Autor Loboda I.
In der Rubrik Zeitschriften haben wir 1 Beitrag für Sie gefunden
-
MerkenHarmonising the Rules on Bioequivalence in Ukraine
Rubrik: europharm
(Treffer aus pharmind, Nr. 04, Seite 477 (2021))
Gielsdorf W | Loboda I | Valueva N | Dobrova A
Harmonising the Rules on Bioequivalence in Ukraine / Reviewing the current Ukrainian and European Union legislation as well as the applicable provisions of the FDA and WHO · Gielsdorf W1, Loboda I2, Valueva N2, Dobrova A2 · 1Healthcare Services & Consulting, Bibertal und SAFEMed, Management Sciences for Health (USAID contractor), Kyiv, Ukraine
Many governments consider generics as an important tool to cap national healthcare spending: in 2018 in the USA cost savings due to generics are estimated at 293 billion US-dollars [ 1 ]. Generic products (including hybrids and biosimilars) represent the by far biggest share in all pharma markets: It is therefore of paramount interest that generics, branded generics and hybrids on the market are safe, efficacious and of good quality. The actual healthcare reform programme in Ukraine is well in line with many similar programmes worldwide, which aim to increase affordability of good quality, efficacious and safe medicines to their population. ...
